Idalopirdine
Drug
H. Lundbeck A S
Total Payments
$56,870
Transactions
1
Doctors
1
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $56,870 | 1 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $56,870 | 1 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With an Acetylcholinesterase Inhibitor (STARBRIGHT) | H. Lundbeck A S | $56,870 | 1 |
Top Doctors Receiving Payments for Idalopirdine
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD PHD | Neurological Surgery | Sun City, AZ | $56,870 | 1 |
Ad
Manufacturing Companies
- H. Lundbeck A S $56,870
Product Information
- Type Drug
- Total Payments $56,870
- Total Doctors 1
- Transactions 1
About Idalopirdine
Idalopirdine is a drug associated with $56,870 in payments to 1 healthcare providers, recorded across 1 transactions in the CMS Open Payments database. The primary manufacturer is H. Lundbeck A S.
Payment data is available from 2018 to 2018. In 2018, $56,870 was paid across 1 transactions to 1 doctors.
The most common payment nature for Idalopirdine is "Unspecified" ($56,870, 100.0% of total).
Idalopirdine is associated with 1 research study, including "Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With an Acetylcholinesterase Inhibitor (STARBRIGHT)" ($56,870).